RISC Protein Stabilization of Nucleic Acid Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid therapeutics, such as microRNA-based therapies and siRNAs, face challenges including limited half-life and inefficient delivery to specific cells, due to degradation by RNases and immunogenicity, as well as off-target effects and toxicity from delivery vectors.
Innovation Solution
The compositions enhance nucleic acid therapeutics by incorporating RNA-induced silencing complex (RISC) proteins, specifically Argonaute 2, and using engineered exosomes or extracellular vesicles as delivery vehicles, which are modified to be devoid of endogenous nucleic acids and equipped with targeting moieties, to stabilize and deliver nucleic acid therapeutics effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If nucleic acid therapeutics are delivered using conventional methods, then therapeutic effect is achieved, but half-life is limited due to degradation by RNases
Solution Approach 1:
The patent introduces RISC proteins (particularly Argonaute 2) as intermediary molecules that bind to nucleic acid therapeutics and protect them from RNase degradation. This mediator approach extends the half-life of nucleic acid therapeutics by shielding them from harmful enzymatic degradation while maintaining their therapeutic function.
Solution Approach 2:
The patent creates composite structures by combining nucleic acid therapeutics with RISC proteins to form ribonucleoprotein complexes. This composite approach provides both the therapeutic nucleic acid sequence and the protective protein scaffold, resulting in enhanced stability and prolonged circulation half-life in vivo.
2Reliability
If delivery vectors are used to deliver nucleic acid therapeutics, then cellular delivery is improved, but immunogenicity and toxicity increase
Solution Approach 1:
The patent extracts and eliminates the harmful delivery vector components while retaining the essential delivery function. By using RISC proteins and engineered exosomes without traditional viral or chemical transfection reagents, the method achieves cellular delivery while removing the source of immunogenicity and toxicity associated with conventional vectors.
Solution Approach 2:
The patent employs biodegradable and naturally occurring delivery vehicles (exosomes and RISC proteins) that are metabolized by the body, replacing persistent synthetic vectors. These disposable-like delivery systems provide transient delivery function without long-term accumulation or chronic immune activation.
3Reliability
If conventional delivery methods are used, then nucleic acid therapeutics reach target cells, but off-target effects occur
Solution Approach 1:
The patent applies local quality enhancement by equipping delivery vehicles with specific targeting moieties that recognize and bind to receptors on target cells. This localized targeting capability ensures that nucleic acid therapeutics are delivered preferentially to intended cells while minimizing exposure and off-target effects in non-target tissues.
4Adaptability or versatility
If endogenous nucleic acids are present in delivery vehicles, then vehicle functionality is maintained, but therapeutic specificity is reduced
Solution Approach 1:
The patent removes endogenous nucleic acids from exosomal delivery vehicles through specific depletion protocols. This extraction process eliminates background nucleic acid contamination that could cause off-target effects, while the exosomal structure and targeting capabilities are preserved through careful engineering.
Solution Approach 2:
The patent modifies the nucleic acid composition parameter of delivery vehicles by depleting endogenous sequences and enriching for or loading with specific therapeutic nucleic acids. This parameter control ensures high therapeutic specificity while maintaining the functional integrity of the delivery vehicle.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach stabilizes miRNAs like miR-34a, prolongs their half-life, and enhances their therapeutic efficacy by delivering RISC proteins alongside nucleic acid therapeutics, reducing immunogenicity and improving targeted delivery, thereby increasing the stability and effectiveness of nucleic acid-based treatments.
Implementation Method 1
The compositions enhance nucleic acid therapeutics by incorporating RNA-induced silencing complex (RISC) proteins, specifically Argonaute 2, to stabilize and deliver nucleic acid therapeutics effectively
Implementation Method 2
using engineered exosomes or extracellular vesicles as delivery vehicles, which are modified to be devoid of endogenous nucleic acids and equipped with targeting moieties, to stabilize and deliver nucleic acid therapeutics effectively
Data Source
AI summary
The compositions for enhancing nucleic acid therapeutics are used in the treatment or prevention of diseases or conditions. The compositions improve the use of nucleic acid therapeutics with the use of enhancing or stabilizing elements, such as RNA-induced silencing complex (RISC) proteins. The compositions include at least one nucleic acid therapeutic or a polynucleotide encoding at least one nucleic acid therapeutic; at least one enhancing or stabilizing element, mutant, variant or modified form thereof, or a polynucleotide encoding at least one enhancing or stabilizing element, mutant, variant or Modified form thereof; and a delivery vehicle, where the delivery vehicle may be exosomes, microvesicles, apoptotic bodies, oncosomes, microparticles, extracellular vesicles, liposomes, nanoparticles, plasmids or vectors. The exosomes or extracellular vesicles may be engineered to be substantially devoid of endogenous nucleic acids by downregulating or inhibiting at least one protein involved in sorting or loading nucleic acids into exosomes or extracellular vesicles.